發(fā)布時間：2018-03-04 03:15

  本文選題：腎透明細胞癌　切入點：血清標志物　出處：《新疆醫(yī)科大學(xué)》2017年碩士論文　論文類型：學(xué)位論文

【摘要】：目的:檢測腎透明細胞癌患者血清中微小RNA-214(miR-214)和微小RNA-106b(miR-106b)手術(shù)前后的表達水平,探討其與臨床病理特征間的相互關(guān)系及臨床應(yīng)用價值。方法:收集45例2013年7月至2016年4月期間我院泌尿外科新診斷為腎透明細胞癌患者手術(shù)前后的血清樣本作為實驗組。另外收集30例健康體檢者的血清樣本作為對照組。采用實時熒光定量PCR技術(shù)檢測各組血清樣本中miR-214和miR-106b的表達水平。結(jié)果:miR-214在術(shù)前、術(shù)后1周、術(shù)后1月及對照組血清相對表達量分別為6.32(4.87,7.91)、4.96(2.88,9.57)、1.21(0.69,3.17)、1.05(0.44,1.45),而miR-106b血清相對表達量分別為4.10(2.62,9.67)、4.46(1.58,6.76)、0.91(0.62,2.55)、1.28(0.56,1.91)。腎透明細胞癌組術(shù)前的血清miR-214相對表達量高于術(shù)后1個月及對照組(Z=-4.247,P0.001;Z=-4.330,P0.001),腎透明細胞癌組術(shù)后1周的血清miR-214表達量也高于術(shù)后1個月及對照組(Z=4.391,P0.001;Z=-4.371,P0.001)。腎透明細胞癌組術(shù)前血清miR-214表達量與術(shù)后1周比較,以及術(shù)后1個月與對照組比較,差異均無統(tǒng)計學(xué)意義(Z=-0.998,P=0.318;Z=-0.872,P=0.383)。腎透明細胞癌組術(shù)前的血清miR-106b相對表達量高于術(shù)后1個月及對照組(Z=-4.206,P0.001;Z=-4.997,P0.001),腎透明細胞癌組術(shù)后1周的血清miR-106b相對表達量也高于術(shù)后1個月及對照組(Z=3.939,P0.001;Z=-4.132,P0.001)。腎透明細胞癌組術(shù)前血清miR-106b相對表達量與術(shù)后1周比較,以及術(shù)后1個月與對照組比較,差異均無統(tǒng)計學(xué)意義(Z=-1.491,P=0.136;Z=-0.377,P=0.706)。根據(jù)腎透明細胞癌患者與健康人血清中miRNAs的表達差異,繪制ROC曲線進行分析,得到miR-214的曲線下面積(AUC)=0.858(95%CI:0.756,0.960;P0.05),敏感性為80.0%,特異性為90.0%;miR-106b的曲線下面積(AUC)=0.876(95%CI:0.783,0.968;P0.05),敏感性為86.7%,特異性為80.0%。結(jié)論:在腎透明細胞癌患者血清中miR-214和miR-106b的相對表達水平較健康對照組明顯升高,在切除腫瘤組織后其表達量均顯著下降,利用ROC曲線法分析,其特異性及敏感性均已經(jīng)達到臨床應(yīng)用價值,是腎透明細胞癌可選的分子標志物。
[Abstract]:Objective: to detect the expression of microRNA-214mmiR-214) and micro-RNA-106bmmiR-106b in serum of patients with clear cell carcinoma of kidney (RCC) before and after operation. To explore the relationship between clinical and pathological features and clinical application value. Methods: 45 patients with renal clear cell carcinoma diagnosed by urology from July 2013 to April 2016 in our hospital were collected as serum samples before and after operation. The serum samples of 30 healthy persons were collected as control group. The expression levels of miR-214 and miR-106b in serum samples of each group were detected by real-time fluorescence quantitative PCR technique. 1 week after operation, The relative expression levels of serum miR-214 in January and control group were 6.32 / 4.87 / 7.91and 4.962.88 / 9.57 respectively, respectively. The relative expression of serum miR-214 in miR-106b was 4.102.62 / 9.67 / 4.461.51.586.766.0.620.62 / 0.62 / 0. 561 respectively. The relative expression of serum miR-214 in clear cell carcinoma group before operation was higher than that in the control group (1 month after operation) and in the control group (P 0.001 Z-4.247g / P 0.001Z-4.330P 0.001), and the relative expression of serum miR-214 in clear cell carcinoma group before operation was higher than that in the control group (P 0.001Z-4.247g P 0.001Z-4.330P 0.001), and in the patients with clear cell carcinoma of kidney, the relative expression of serum miR-214 was higher than that in the control group (P 0.001), and in the patients with renal clear cell carcinoma, the relative expression of serum miR-214 was higher than that in the control group (P 0.001). The expression of serum miR-214 in the latter 1 week was also higher than that in the control group and the control group. The expression of serum miR-214 in the renal clear cell carcinoma group was higher than that in the control group at 1 week after operation, and the expression of serum miR-214 in the renal clear cell carcinoma group was higher than that in the control group at 1 week after operation. And 1 month after operation compared with the control group, There was no significant difference between the two groups. The relative expression of serum miR-106b in clear cell carcinoma group before operation was higher than that in control group at 1 month after operation. The relative expression of serum miR-106b in clear cell carcinoma group was also higher than that in 1 month after operation and in control group. The relative expression of serum miR-106b in clear cell carcinoma group was also higher than that in one month after operation and in the control group. The relative expression of serum miR-106b in the renal clear cell carcinoma group was also higher than that in the control group at 1 week after operation. The relative expression of serum miR-106b in the renal clear cell carcinoma group was higher than that in the control group at 1 month after operation. The relative expression of serum miR-106b in the renal clear cell carcinoma group was compared with that in the first week after operation. Compared with the control group, there was no significant difference between the two groups 1 month after operation. According to the difference of miRNAs expression between the patients with renal clear cell carcinoma and the healthy people, the ROC curve was plotted. Under the curve of miR-214, the area under the curve of miR-214 is 0.858C95 CI: 0.756U 0.960g P0.05, the sensitivity is 80.0and the specific area is 90.0106b. The area under the curve is 0.87695CIW 0.783C: 0.96P0.05, the sensitivity is 86.7, the specificity is 80.00.Conclusion: the relative expression level of miR-214 and miR-106b in the serum of patients with clear cell carcinoma of kidney is obviously higher than that of the healthy control group, and the relative expression of miR-214 and miR-106b in the serum of the patients with clear cell carcinoma of kidney is obviously higher than that of the healthy control group, and the relative expression of miR-214 and miR-106b in the serum of the patients with clear cell carcinoma of kidney is obviously higher than that of the control group. The expression levels of tumor tissues decreased significantly after resection. The specificity and sensitivity of these two markers have reached the clinical application value by ROC curve analysis, which is an optional molecular marker for renal clear cell carcinoma.
【學(xué)位授予單位】：新疆醫(yī)科大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R737.11

【相似文獻】

相關(guān)期刊論文 前10條

1 楊勇;小兒腎透明細胞癌1例報告[J];陜西醫(yī)學(xué)雜志;2003年02期

2 易仁亮;老年雙腎透明細胞癌1例報告[J];實用老年醫(yī)學(xué);2005年03期

3 楊華,王華慶;腎透明細胞癌的全身治療現(xiàn)狀及進展[J];國外醫(yī)學(xué).外科學(xué)分冊;2005年06期

4 李云輝,林華歡;腎透明細胞癌術(shù)后遠處轉(zhuǎn)移3例[J];廣東醫(yī)學(xué);2005年01期

5 胡蜀雯;劉華麗;;超聲診斷以囊性病變?yōu)橹鞯哪I透明細胞癌1例[J];臨床超聲醫(yī)學(xué)雜志;2007年03期

6 石泓哲;李長嶺;;紅色膠狀腎透明細胞癌的臨床及病理特點——附2例報告[J];癌癥進展;2007年06期

7 歐陽可雄;陳偉良;黃志權(quán);李勁松;張樹標;;腎透明細胞癌伴下頜骨轉(zhuǎn)移1例報告[J];中國口腔頜面外科雜志;2008年01期

8 祖強;洪寶發(fā);;受體酪氨酸激酶抑制劑對于晚期腎透明細胞癌的靶向治療作用[J];中國藥物應(yīng)用與監(jiān)測;2008年02期

9 藍建發(fā);陳一戎;潘華;史葆光;段國蘭;;小窩蛋白-1與血小板反應(yīng)蛋白在腎透明細胞癌中的表達及其意義[J];現(xiàn)代泌尿外科雜志;2009年03期

10 趙彥博;李麗;;腎透明細胞癌的螺旋CT表現(xiàn)與病理對照分析[J];中國煤炭工業(yè)醫(yī)學(xué)雜志;2011年11期

相關(guān)會議論文 前10條

1 劉婧;;腎透明細胞癌伴全身轉(zhuǎn)移在全身擴散加權(quán)成像的影像規(guī)律[A];中華醫(yī)學(xué)會第16次全國放射學(xué)學(xué)術(shù)大會論文匯編[C];2009年

2 耿江;方祖軍;吳忠;姜昊文;鄭捷;丁強;;腎透明細胞癌術(shù)后遠處轉(zhuǎn)移(附15例報告)[A];第十五屆全國泌尿外科學(xué)術(shù)會議論文集[C];2008年

3 桂定文;張青漢;;腎透明細胞癌頭皮轉(zhuǎn)移一例報告[A];第七次中國中西醫(yī)結(jié)合泌尿外科學(xué)術(shù)年會暨第二次廣東省中西醫(yī)結(jié)合泌尿外科學(xué)術(shù)年會論文集[C];2009年

4 凌月蓉;葉軍;;腎透明細胞癌彩色多普勒超聲表現(xiàn)分析[A];中國超聲醫(yī)學(xué)工程學(xué)會第八屆全國腹部超聲學(xué)術(shù)會議論文匯編[C];2010年

5 吳俊;梅長林;趙海丹;戴兵;劉亞偉;;多囊蛋白-1在腎透明細胞癌及常染色體顯性多囊腎病患者體液中含量的比較研究[A];中華醫(yī)學(xué)會腎臟病學(xué)分會2006年學(xué)術(shù)年會論文集[C];2006年

6 柏瑞;歐陜興;林偉光;;雙腎透明細胞癌胰腺轉(zhuǎn)移一例報告[A];中華醫(yī)學(xué)會第十三屆全國放射學(xué)大會論文匯編（下冊）[C];2006年

7 尹森琴;鄭勇明;江時忠;朱斌;陳立忠;章明圖;;腎透明細胞癌的螺旋CT表現(xiàn)與病理對照研究[A];2007年浙江省放射學(xué)學(xué)術(shù)年會論文匯編[C];2007年

8 畢偉;徐麗偉;徐春媚;董曉秋;;腎透明細胞癌超聲造影模式及定量指標分析[A];中國超聲醫(yī)學(xué)工程學(xué)會第七屆全國腹部超聲學(xué)術(shù)會議學(xué)術(shù)論文匯編[C];2007年

9 徐麗偉;徐春媚;畢偉;董曉秋;;腎透明細胞癌超聲造影模式與其病理分化程度的相關(guān)性[A];中國超聲醫(yī)學(xué)工程學(xué)會第七屆全國腹部超聲學(xué)術(shù)會議學(xué)術(shù)論文匯編[C];2007年

10 鄭宇朋;;腎透明細胞癌三次轉(zhuǎn)移至鼻腔[A];第十五屆全國泌尿外科學(xué)術(shù)會議論文集[C];2008年

相關(guān)重要報紙文章 前2條

1 張中橋;Survivin在腎透明細胞癌中起重要作用[N];中國醫(yī)藥報;2006年

2 王茜;隱瞞病情可能更會嚇壞患者,好心態(tài)是良藥[N];新華每日電訊;2007年

相關(guān)博士學(xué)位論文 前10條

1 趙作輝;腎透明細胞癌的蛋白質(zhì)組學(xué)研究[D];山東大學(xué);2015年

2 王暉;腎透明細胞癌硬脂酰輔酶A去飽和酶I對AKT信號通路的調(diào)控機制的研究[D];上海交通大學(xué);2014年

3 葛南;MGMT基因表達在腎細胞癌治療中的作用研究[D];山東大學(xué);2015年

4 趙建軍;腎透明細胞癌中miR-630的表達及與其臨床生物學(xué)行為關(guān)系的研究[D];河北醫(yī)科大學(xué);2014年

5 夏秋媛;SWI/SNF染色質(zhì)重塑復(fù)合物亞基BRM在腎透明細胞癌中缺失及其機制研究[D];南京大學(xué);2014年

6 李春景;PGAM1在腎透明細胞癌中的表達、臨床意義及其功能研究[D];南方醫(yī)科大學(xué);2016年

7 高宇;KLF6基因表達下調(diào)在腎透明細胞癌遠處轉(zhuǎn)移中的作用及其機制研究[D];中國人民解放軍醫(yī)學(xué)院;2016年

8 許力為;MiR-186-5p在腎透明細胞癌侵襲轉(zhuǎn)移和血管生成中作用的研究[D];浙江大學(xué);2016年

9 王明超;睪丸孤核受體4（TR4）在腎透明細胞癌侵襲轉(zhuǎn)移中作用及其機制的研究[D];浙江大學(xué);2016年

10 朱冶華;腎透明細胞癌侵襲性與CT強化特征相關(guān)性研究[D];上海交通大學(xué);2015年

相關(guān)碩士學(xué)位論文 前10條

1 秦杰;腎透明細胞癌3、7、8、9、17號染色體的雜合性缺失研究[D];大連醫(yī)科大學(xué);2009年

2 丁家寶;E2F1及EGR-1在腎透明細胞癌中的表達及意義[D];河北醫(yī)科大學(xué);2015年

3 郭巖松;ERCC1在腎透明細胞癌中的表達及其意義[D];河北醫(yī)科大學(xué);2015年

4 朱鑫;HDAC1及E2F1在腎透明細胞癌中的表達及意義[D];河北醫(yī)科大學(xué);2015年

5 趙輝;DECT皮髓早期增強序列圖像對腎透明細胞癌的診斷價值[D];寧夏醫(yī)科大學(xué);2015年

6 魏晉艷;能譜CT成像在腎透明細胞癌術(shù)前分級評估 中的價值研究[D];蘭州大學(xué);2015年

7 高裕;CREPT在腎透明細胞癌的作用機制研究[D];寧夏醫(yī)科大學(xué);2015年

8 王鵬;緊密連接蛋claudin-4在腎透明細胞癌中的表達及其預(yù)后意義[D];中國人民解放軍軍事醫(yī)學(xué)科學(xué)院;2015年

9 牛少曦;miR-223在腎透明細胞癌中的表達和作用[D];中國人民解放軍醫(yī)學(xué)院;2015年

10 李金濤;腫瘤干細胞ALDH1和ABCG2在腎透明細胞癌中的表達及其臨床意義[D];新鄉(xiāng)醫(yī)學(xué)院;2015年

，

本文編號：1563888